From the beginning of the colon polyp study, the safety monitors had noted an increased rate of hypertension among the Vioxx group . In addition, in 2003 and earlier this year, they found that more people in the Vioxx group were having cardiovascular events than in the placebo group . The numbers were small, in part because people with heart disease had been screened out of the trial, but the trend had been worrisome and the latest data were striking: After 18 months on the drug, the Vioxx group was clearly having more